THC-O and THCP: What Research Really Shows About Potency, Safety, and Legal Status

THC-O and THCP are often marketed as exceptionally strong alternatives to traditional delta-9 THC. But the evidence behind those claims is far less conclusive than product labels and promotional material suggest. The two compounds are also fundamentally different: THC-O is a semi-synthetic acetate derivative, while THCP is a naturally occurring cannabinoid found only in trace amounts in cannabis.

Both remain poorly studied in humans. Available research points to meaningful safety concerns—especially for inhaled THC-O products—and does not support the idea that either compound is simply “33 times” or “three times” more intoxicating than delta-9 THC.

THC-O is a laboratory-produced acetate derivative

THC-O, short for THC-O-acetate, is made by chemically modifying THC. Commercial products are generally produced by converting hemp-derived CBD into delta-8 or delta-9 THC and then adding an acetate group using acetic anhydride. This process is different from extracting a cannabinoid directly from the plant, and poorly controlled manufacturing may leave behind unwanted chemical by-products or contaminants.

Claims that THC-O is three times more potent than delta-9 THC are not supported by robust human clinical research. Much of the compound’s reputation comes from marketing and anecdotal reports, including claims that it produces psychedelic effects resembling mescaline or other hallucinogens. However, a 2023 study examining reports of THC-O’s supposed psychedelic effects found limited evidence for a distinctive psychedelic experience. The findings were based on self-reported use rather than a controlled clinical trial, so they cannot establish THC-O’s safety or therapeutic value.

Why vaping THC-O raises particular concerns

The most significant warning about THC-O concerns the acetate group itself. Research has found that heating cannabinoid acetates can produce ketene, a highly toxic gas associated with serious lung injury. In a 2022 report, researchers analyzed commercially available THC-O products and found evidence that THC-O acetate could generate ketene under vaping conditions. Their findings were published in “Vaping THC-O Acetate: Potential for Another EVALI Epidemic”.

This research does not prove that every THC-O product or every use will cause lung damage. It does, however, provide a credible chemical reason to avoid vaping or dabbing THC-O acetate. Combustion and high-temperature heating may also create additional toxic compounds, and the contents of unregulated products may not match their labels.

The concern is separate from the broader risks of cannabis intoxication. The FDA has warned that unapproved cannabinoid products may contain inconsistent concentrations, contaminants, or by-products from chemical processing. Adverse effects reported with intoxicating cannabinoid products can include anxiety, dizziness, confusion, vomiting, hallucinations, loss of consciousness, and impaired judgment.

THCP is natural, but usually present only in trace amounts

THCP—formally known as delta-9-tetrahydrocannabiphorol—was identified in cannabis in 2019. The original researchers found it in extremely small quantities and described it in the original Scientific Reports study on THCP.

In laboratory experiments, THCP showed a much greater binding affinity for the CB1 receptor than delta-9 THC. The researchers also observed THC-like effects in mice. Those results help explain why THCP may be pharmacologically powerful, but they do not mean that a person will experience a high exactly 33 times stronger than an equivalent dose of delta-9 THC.

The widely repeated “33 times stronger” figure refers primarily to receptor-binding results in vitro, not to a controlled comparison of intoxication in humans. Receptor affinity is only one factor in how a drug affects the body. Dose, absorption, metabolism, product purity, tolerance, and the route of administration all influence the experience.

There is still little clinical information about THCP. Case reports published since its appearance on the consumer market have described severe intoxication after oral exposure, including confusion and psychiatric or neurological symptoms. These reports cannot determine how frequently such reactions occur, but they underscore the uncertainty surrounding products sold in concentrated forms.

THC-O and THCP are not interchangeable

• Origin: THC-O is produced through chemical modification; THCP occurs naturally in cannabis but generally only in trace amounts.
• Evidence: THC-O has limited human research and no established safe or therapeutic dose. THCP has strong preclinical receptor and animal findings but similarly little human pharmacology.
• Potency claims: Neither “three times stronger” for THC-O nor “33 times higher” for THCP should be treated as a reliable measure of the human high.
• Inhalation risk: THC-O acetate presents an additional concern because heating it may generate ketene.
• Product quality: Concentrates sold outside regulated cannabis systems may contain inaccurate labels, residual solvents, reaction by-products, or other cannabinoids.

Legal status is complicated and location-dependent

The 2018 Farm Bill defined hemp as cannabis and cannabis derivatives containing no more than 0.3% delta-9 THC by dry weight. That language helped create a market for intoxicating hemp-derived products, but it did not clearly resolve the status of every chemically modified cannabinoid.

The federal government’s position has also conflicted with court decisions. In a February 13, 2023 opinion letter, the Drug Enforcement Administration stated that THC-O is a Schedule I controlled substance because it does not occur naturally in cannabis and is produced synthetically. In contrast, the U.S. Court of Appeals for the Fourth Circuit reached a different conclusion in a September 4, 2024 case, holding that a cannabis-derived THC-O product could fall within the Farm Bill’s definition of hemp if it met the delta-9 THC threshold.

The result is not a nationwide guarantee that THC-O or THCP products are legal. Federal interpretations, court rulings, state laws, enforcement policies, and product composition can all matter. The Congressional Research Service’s 2025 report on hemp-derived THC products describes the continuing legal conflict and the growing number of states that restrict or prohibit intoxicating hemp-derived cannabinoids.

The practical takeaway

THC-O and THCP should not be treated as well-understood upgrades to ordinary cannabis. THC-O is associated with a specific inhalation hazard because its acetate structure may produce ketene when heated. THCP’s natural origin does not make concentrated commercial products safe; the compound’s strong laboratory activity and limited human data make dose and impairment difficult to predict.

Consumers should be especially cautious with products that make dramatic potency claims, lack independent laboratory testing, or are intended to be vaped or dabbed. Until controlled human studies establish reliable information about dosing, metabolism, long-term effects, and product safety, the most accurate description of both cannabinoids is not “stronger and better,” but novel, intoxicating, and insufficiently studied.